Anterior chamber bevacizumab for rubeotic glaucoma secondary to retinal artery occlusion☆

Rajan Bhojwani; Simon P. Kelly

doi:10.1016/j.artres.2009.06.001

<Previous Article In Issue

Volume 3, Issue 3, September 2009, Pages 122 - 123

Anterior chamber bevacizumab for rubeotic glaucoma secondary to retinal artery occlusion☆

Authors

Rajan Bhojwani^a^{, b}^{, *}, Simon P. Kelly^a

^aBolton Hospitals NHS Foundation Trust, Minerva Road, Bolton BL4 0JR, UK

^bManchester Royal Eye Hospital, Oxford Road, Manchester M13 9WH, UK

^☆

Financial support (grants) and proprietary interests: None.

^*Corresponding author. Bolton Hospitals NHS Foundation Trust, Minerva Road, Bolton BL4 0JR, UK. Tel.: +44 1204 390 390. E-mail address: bhojwani@doctors.net.uk (R. Bhojwani).

Corresponding Author

Rajan Bhojwani

Received 30 May 2009, Accepted 11 June 2009, Available Online 5 July 2009.

DOI: 10.1016/j.artres.2009.06.001 How to use a DOI?
Keywords: Anterior chamber; Bevacizumab; Rubeotic glaucoma; Central retinal artery occlusion
Abstract: A 73-year-old Caucasian female, presented with sudden loss of vision in the right eye due to a central retinal artery occlusion (CRAO). The patient presented acutely 10-weeks later with a painful right eye due to rubeosis; intraocular pressure (IOP) was 67mmHg. A single anterior chamber injection of bevacizumab was performed as an adjunct combination therapy for her neovascularisation. Informed consent to the patient included a detailed explanation of the medication licensing status. 1-week post injection the cornea was clear and there was less rubeosis. Pan-retinal photocoagulation (PRP) was performed and 1 month later there was a marked reduction in rubeosis iridis. At 6 months follow up the patient remains comfortable on prednisolone acetate 1% OD and atropine 1% OD; IOP is 24. As the main trigger for such neovascularisation is retinal ischaemia, the incidence of rubeosis in CRAO is relatively low. Successful combination treatment of rubeosis following CRAO with a single intravitreal injection of anti-VEGF followed by PRP has been reported. In our opinion anterior chamber injection of anti-VEGF may be less invasive than intravitreal delivery. Although there are emerging reports regarding the successful use and efficacy of the anterior chamber route of administration for the treatment of rubeosis from venous occlusion, no such reports have been published following CRAO.
Open Access: This is an open access article distributed under the CC BY-NC license.

Download article (PDF)
View full text (HTML)

<Previous Article In Issue

Journal: Artery Research
Volume-Issue: 3 - 3
Pages: 122 - 123
Publication Date: 2009/07/05
ISSN (Online): 1876-4401
ISSN (Print): 1872-9312
DOI: 10.1016/j.artres.2009.06.001 How to use a DOI?
Open Access: This is an open access article distributed under the CC BY-NC license.

Cite this article

ris enw bib

TY  - JOUR
AU  - Rajan Bhojwani
AU  - Simon P. Kelly
PY  - 2009
DA  - 2009/07/05
TI  - Anterior chamber bevacizumab for rubeotic glaucoma secondary to retinal artery occlusion☆
JO  - Artery Research
SP  - 122
EP  - 123
VL  - 3
IS  - 3
SN  - 1876-4401
UR  - https://doi.org/10.1016/j.artres.2009.06.001
DO  - 10.1016/j.artres.2009.06.001
ID  - Bhojwani2009
ER  -

download .riscopy to clipboard